1349. Global Surveillance of Cefiderocol against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
  • P1349_IDweek2018_Cefiderocol_Tsuji_final.pdf (717.2 kB)
  • Background: Cefiderocol (CFDC) is a novel parenteral siderophore cephalosporin with potent activity against a wide range of Gram-negative pathogens including carbapenem-resistant strains. Additionally, a recently conducted in vivo murine-based study has demonstrated an incremental exposure-response profile over a dose range without the appearance of adaptive resistance. In this study, we evaluated the in vitro activity of CFDC and comparator agents against clinical isolates collected in 2015-2016 from North America from SIDERO-WT-2015 surveillance study. Methods: A total of 3602 isolates (2470 Enterobacteriaceae, 223 A. baumannii, 85 Acinetobacter spp., 619 P. aeruginosa, 165 S. maltophilia and 17 Burkholderia cepacia, and 23 Burkholderia spp.) collected from the USA and Canada in 2015–2016 were tested. MICs were determined for CFDC, cefepime (FEP), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), ciprofloxacin (CIP), colistin (CST), and meropenem (MEM) by broth microdilution and interpreted according to CLSI guidelines. As recommended by CLSI, cefiderocol was tested in iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB). Carbapenem non-susceptible (Carb-NS) strains were defined as MEM MIC ≥2 µg/mL for Enterobacteriaceae, and ≥4 µg/mL for non-fermenters. Results: CFDC exhibited potent in vitro activity against 3602 strains of Gram-negative bacteria with an overall MIC90 of 0.5 mg/mL. As shown in the following table, MIC90 of CFDC against P. aeruginosa, A. baumannii, S. maltophilia, and Enterobacteriaceae including the subset of Carb-NS isolates were 0.5, 2, 0.5 and 0.5 mg/mL, respectively. At 4 mg/mL, CFDC inhibited the growth of 99.6% of the isolates while 18.1%, 12.6% and 13.8% showed resistance to CZA, C/T, and CST, respectively. Conclusion: CFDC demonstrated potent in vitro activity against the teat isolates collected from North America with greater than 99.6 % of isolates having MIC values ≤4 mg/mL, including Carb-NS isolates of A. baumannii, P. aeruginosa, and Enterobacteriaceae. These findings indicate that this agent has high potential for treating infections caused by these problematic organisms.
    Enterobacteriaceae 2470 0.5 4 0.5 1 >8 >8 ≤0.06
    P. aeruginosa 619 0.5 16 8 2 >8 2 8
    A. baumannii 223 2 >64 >64 >64 >8 1 >64
    S. maltophilia 165 0.5 >64 64 >64 >8 8 >64
    Masakatsu Tsuji, Ph.D1, Meredith Hackel, PhD, MPH2, Roger Echols, MD, FIDSA3, Yoshinori Yamano, Ph.D1 and Dan Sahm, PhD2, (1)SHIONOGI & CO., LTD., Osaka, Japan, (2)International Health Management Associates, Inc., Schaumburg, IL, (3)ID3C, Easton, CT


    M. Tsuji, SHIONOGI & CO., LTD.: Employee , Salary .

    M. Hackel, IHMA, Inc: Employee , Salary .

    R. Echols, None

    Y. Yamano, SHIONOGI & CO., LTD.: Employee , Salary .

    D. Sahm, IHMA, Inc: Employee , Salary .

    See more of: Novel Agents
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.